Condition
Prostate Inflammation
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed1
Enrolling By Invitation1
Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06505356Not ApplicableEnrolling By Invitation
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage
NCT06684626Phase 3CompletedPrimary
The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment
NCT05629494Phase 4Recruiting
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
NCT02961114Phase 1Withdrawn
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
Showing all 4 trials